ghk-cu peptide cancer risk GHK-CU – Research Peptide |

The FDA moved these peptides to Category 2 primarily due to a lack of large-scale, randomized, placebo-controlled human trials demonstrating their safety and efficacy

Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health

Source: The potential of GHK as an anti-aging peptide (2020) Claim 2: Intranasal administration bypasses the blood-brain barrier (BBB) to enhance central nervous system (CNS) delivery

Cells were incubated with the respective fluorescent probes in the dark at 37C for 30 min and then washed with PBS

The earliest sign of response is reduced shedding at 4 to 8 weeks, but visible new growth requires 8 to 16 weeks and meaningful density change takes 4 to 6 months

Chen S, Wang H, Xu P, Dang S, Tang Y